Variations in cell therapy reimbursement across the Big5EU
|
|
- Marian Brooks
- 7 years ago
- Views:
Transcription
1 Variations in cell therapy reimbursement across the Big5EU Jesper Jorgensen and Panos Kefalas May 2015 Catapult is an Innovate UK programme.
2 Overview This presentation describes how pricing and reimbursement (P&R) frameworks for cell therapies vary by: A. Geography across the Big5EU (France, Germany, Italy, Spain and UK) B. Therapy features: We focus on: magnitude of incremental benefit vs alternative therapeutic approaches size of target population regulatory status The hospital setting (in- and out-patient) The public payers
3 Licensed ATMP category
4 Pricing of innovative licensed therapies in Big5EU has shifted towards value-based models What is it? Examples Comments Cost-based Competitor-based Value-based Price based on costs, expected sales and margins Cost-plus pricing Becoming obsolete Exception: unlicensed ATMPs Price driven by competition Penetration pricing Reference group pricing Enforced for undifferentiated products Price based on evidence of therapeutic /economic value to the customer Value-based pricing Typical approach for differentiated products 4
5 Value-based assessments link price potential to the magnitude of the novel therapy s added-value over the standard of care (SOC) PRINCIPLES OF VALUE-BASED ASSESSMENTS V = RV + PDV - NDV Differentiating Value Includes: PDV Negative differentiation value (NDV) Positive differentiation value NDV Clinical effectiveness Economic effectiveness: budget impact, costminimisation, cost-effectiveness, cost-utility, costconsequence Comparative data against the SOC/BSC per country is required: V Gold-standard: H2H RCT RV Reference value (SOC) Indirect comparisons (NMA) can be leveraged when H2H not available Comparisons should be based on balanced data Data manipulation via regression: Observational vs RCT For a given indication, V varies depending on therapeutic positioning 5
6 QoL (utility score) ATMP In the UK the incremental cost-effectiveness ratio (ICER) is widely used to inform price potential Cost B Cost A ICER = QALY B QALY A QALYs = Life expectancy (life years) x Quality of life (QoL) utility Costs Utility ranges from 0 (death) to 1 (full health) NHS and PSS costs (wider societal costs excluded ICER thresholds for non-rare diseases (operated by UK HTA bodies: NICE, SMC,AWMSG) 20-30K/QALY; exact figure depends on: certainty on QoL and ICER; degree of innovation For end-of-life treatments and for small populations a higher threshold can be considered Treatment A Treatment B EXCEPTIONS! Very small patient populations Willingness-to-pay increases as : disease burden increases Life Years QALYs gained (B vs A) target population decreases 6
7 ATMP The ICER calculation is based on a therapy -specific model that captures health states, time-dependent transitions, outcomes and uncertainty Model Type e.g. decision tree, state transition Markov model, DES, transmission model Analysis: Cohort simulation (lack of IPD), Microsimulation Time horizon: Up to 100 yearly cycles Discount rate: 3.5% Health States (and transitions): as per disease trajectory Pay-offs: cost, utility and life years Model uncertainty is addressed through sensitivity analysis Deterministic: univariate / multivariate Probabilistic: parametric / non-parametric (bootstrapping) Structural
8 ATMP Given a certain level of uncertainty in model variables, a health economically justified price results in the majority of ICER values falling below the ICER threshold ICER scatterplot generated through a Monte Carlo simulation Software: TreeAge Pro
9 ATMP Unlike UK, in Germany ICER thresholds are not in use; clinical benefit, budget impact and international price referencing are the key drivers of reimbursed price potential A clinical benefit assessment (by the Joint Federal Committee [G-BA] and the Institute for Quality and Efficiency in Healthcare [IQWiG]) is the starting point for reimbursement for the majority of novel therapies launching The early benefit assessment rates the incremental clinical effectiveness of the novel therapy vs a relevant comparator in Germany The National Association of Statutory Health Insurance Funds (GKV Spitzenverband) negotiate price based on the clinical benefit assessment and budget impact considerations Therapies with no additional benefit are included in price referencing groups (if available) International price referencing (based on a basket of 15 EU countries) is applied by arbitration in cases where an additional benefit is recognised, but no agreement is reached on price Free pricing applies for therapies with annual revenue < 1M, or for hospital-only products covered through existing DRG tariffs Benefit assessment (AMNOG) Price referencing Price negotiation Level of added benefit No (fehlt) Not quantifiable Minor/ marginal (gering) Considerable benefit (beträchtlich) Significant/ major (erheblich)
10 Benefit ATMP Under certain circumstances cost-benefit analysis may also be a driver in determining price CBA: Efficiency Frontier 3 2 E 1 D B A Net costs / Patient C Manufacturers can request a costbenefit-analysis (CBA) to be conducted by IQWiG in two scenarios: The benefit assessment finds no additional benefit, but the product cannot be included in a reference price group (e.g. new mechanism of action), or The manufacturer rejects the international price-referencing to EU15 Numbers 1-3 represent three hypothetical therapies The blue line, the efficiency frontier, represents the willingness to pay (needed to access the more expensive but more efficient therapies Rectangles A, B, C represent therapies of negative efficiency, i.e. more expensive and less beneficial than existing options (not reimbursed) Triangles D, E represent therapies that are not inefficient, but less efficient than the frontier New treatments exceeding the existing cost and benefit levels can be considered acceptable if they are above the extension of the existing willingness to pay
11 EU4* price corridor ATMP In France, the magnitude of incremental clinical benefit (ASMR) drives the choice of the pricing framework applied ASMR Definition Impact on pricing I II III Therapeutic breakthrough Important improvement Modest improvement Based on prices in EU4 (Germany, Italy, Spain and UK) and supporting cost-effectiveness data IV Minor improvement Parity or small premium over comparator V No/ weak improvement Discount to comparator Price ILLUSTRATIVE The national authority for health (HAS) assesses the added clinical benefit (ASMR) of new treatments vs SOC The pricing committee of the MoH (CEPS) negotiates price based on ASMR score, expected sales volumes, and, for treatments with ASMR I-III, cost-effectiveness No explicit ICER thresholds apply Similar to Germany, free pricing applies for hospital-only products covered sufficiently by existing DRG tariffs Price/volume agreements are commonly used to limit budget impact uncertainty; price is discounted stepwise at confidential volume thresholds Price below the EU4 corridor if HE evidence is inadequate and inconclusive ASMR III ASMR II ASMR I Added benefit
12 ATMP The Italian pricing committee of the National Medicines Agency (AIFA) leverages several factors in price negotiations List price Improved QoL Improved efficacy CONCEPTUAL Budget Impact Disease severity and availability of options Contribution to GDP; lobbying and political relations EU prices* Added benefits AIFA determines whether a new therapy is classified as innovative, based on clinical effectiveness and disease burden It sets the price and the conditions for reimbursement Being innovative helps escape existing pricing benchmarks however: Funding and use is restricted to certain centres, and patient outcomes must be recorded in product-specific AIFA registries Establishing registries for new product can be a hurdle and delay actual adoption An annual fee of 30,000 is levied by the AIFA for each registry Whereas the 21 regions normally have the final say on whether to provide certain treatments, all innovative products must be provided across Italy Mandatory and negotiated (confidential) national, regional and local level discounts are the norm which can result in considerable differences in net price across the country Payment-for-performance is also common for innovative treatments Rebates may be linked to achieving / not achieving pre-specified clinical outcomes (payment by results) and/or exceeding pre-specified budget caps * Typically France, Germany, Spain and the UK
13 ATMP Cost-effectiveness may be accounted for, but no formal requirements exist; budget impact is key A. Cost-effectiveness National level Cost effectiveness analysis is not mandatory in P&R decisions, and although AIFA considers the evidence submitted, it applies no standard requirements for methodology or threshold values Regional level Some Regions e.g. Veneto, Emilia Romagna, Tuscany have their own independent HTA capabilities, however they can also reference HTAs done in other countries (typically England and Scotland) Therefore, regional and local funding decisions in Italy may be negatively affected by negative reimbursement recommendations in the UK Local level Hospitals typically focus on cost offsets e.g. reductions in length of stay and hospitalization costs, as well as the impact on the drug budget B. The main economic value driver across all levels is budget impact The main focus for budget impact analyses is one-year horizon which limits the value proposition for treatments with long-term benefits 13
14 ATMP Spain is a highly decentralised market where P&R decisions are made at national, regional and local level Internal price referencing Novel therapy is benchmarked against existing therapeutic alternatives in Spain International price referencing Pricing authorities commonly reference the cheapest available prices in the Euro zone Tight budget constraints have increased decision-makers price-sensitivity A ceiling price for reimbursement is determined at national level Authorities reference comparator drugs and EU countries with lowest prices Impact on GDP (e.g. through industry presence in Spain) is considered Pricing is shifting towards value-based, however budget control is priority Value-based pricing tends to be applied in conjunction with risk-sharing agreements e.g. ChondroCelect: (100% refund if failure at year one; 75% if yr2, and 50% if yr3) The 17 regions make decisions on conditions for inclusion in regional formularies, and negotiate prices below national ceiling price Hospitals decide on formulary inclusion and negotiate prices further
15 ATMP HE considerations are mainly driven by BI; CE is compulsory, but given the budgetary constraints, it is of uncertain impact on pricing and reimbursement Budget impact (BI) is the main analysis employed by decision-makers Cost-effectiveness (CE) can be employed but plays a less defined role: Nationally: P&R authorities request CE analysis by manufacturers: The pricing benchmark ultimately applied by authorities may be different from the comparator used in the CE analysis No explicitly defined threshold; implicit threshold is 30,000 per QALY Regionally: Only six out of the 17 regions have HTA agencies that may conduct CE analysis (Catalonia being the most advanced) Regions without HTA capability may rely on assessments conducted elsewhere Locally: The GENESIS group provides a framework for assessment methodologies at hospital level (including CE, cost minimisation and number needed to treat) It also commonly references evaluations performed in other countries, e.g. NICE (England and Wales), CADTH (Canada), SMC (Scotland), NPS-RADAR (Australia)
16 ATMP Across Big5EU additional funding mechanisms exist to address funding gaps from DRG tariffs Innovative therapies with a favourable reimbursement decision (at national/ regional level) are typically funded through one of the following mechanisms: Revise/ update existing DRG (diagnosis-related group) tariff Create new DRG and tariff Provide supplementary funding Country France Supplementary funding for hospital products Hors T2A funding restricted to high-cost therapies with: ASMR I-III, or Germany Italy Spain UK ASMR IV-V against a comparator with ASMR I-III Temporary funding (NUB), negotiated between individual hospitals and sickness funds; different tariffs apply across hospitals Permanent funding (ZE); tariffs set nationally File F funding for hospital products, decided by individual regions DRGs not widely used; regions rarely agree to supplementary funding; hospitals have to absorb costs (impacting uptake) DRG exclusions/top-up payments, decided by NHS Monitor Cancer Drugs Fund ( 340M p.a.) available for those not approved by NICE (England)
17 ATMP The size of the target population has P&R implications Willingness to pay is generally higher in very rare diseases due to budget impact and disease burden considerations In payer negotiations, the definition of rarity is not explicit, and at the discretion of decision-makers, (unlike regulatory definitions of orphan, and ultra-orphan*) Country France Germany Italy Spain UK Impacts price/volume agreement Size of target population Forecasted sales determine P&R (abbreviated P&R submission for < 50M p.a., free pricing for < 1M p.a.) Budget impact is central to P&R NICE HSTE relevant to chronic treatments that target <500 patients/ provides greater flexibility with ICER thresholds For NHS Specialised Services ICER thresholds less relevant e.g. Cerezyme commissioned for the treatment of Gaucher s (prevalence 270) at an ICER of 391,244 <20 patients p.a: individual funding requests (rather than formal assessments) *Orphan is defined by prevalence <5/10,000 ; Ultra orphan is defined by prevalence <1/50,000
18 ATMP Only UK provides clear HTA guidance on how long-term claims can be substantiated through extrapolations To bridge the gap between short-term data and long-term claims a regression framework is applied Specified parametric and semi-parametric models are fitted Optimal model selected based on statistical considerations and biological plausibility Fitted survivor function (using example trial data) NICE Decision Support Unit Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials extrapolation with patient-level data, March 2013
19 ATMP Innovative pricing agreements are used across the Big5EU to address clinical and economic uncertainties EU Payers are increasingly resistant to budget uncertainties Uncertainties arise from: Inconclusive clinical and cost effectiveness data at launch Variation in individual patient needs for dosing and length of treatment Types of pricing agreements in operation: Financially-based (most common due to lower administrative burden) Discounts or rebates Outcomes-based, e.g. If value is proven, the negotiated price remains (if not, it decreases) Risk-sharing on individual patient basis e.g. ChondroCelect in Spain: 100% refund if failure at year one 75% refund if failure at year two 50% refund if failure at year three Post-launch evidence generation required 19
20 Other categories: Minimally Manipulated Cell Therapies Hospital Exemptions Compassionate Use
21 Depending on the market, certain regulatory categories of cell therapies can bypass formal P&R assessments Minimally manipulated cell therapies (MMCs) In France, Germany and UK similar P&R assessments apply to MMCs and ATMPs In Italy and Spain, MMCs can bypass national/regional P&R assessments and be assessed by hospitals only Hospital exemptions / Specials Price often determined on a cost-plus basis (rather than value-based) Exception Spain: Need to be supplied on a not-for-profit basis Compassionate use In Germany the manufacturer has to provide treatment free of charge In the other 4 markets price is set freely In France, free-pricing can be penalised through post-launch rebates (ATU) 21
22 Cell Therapy Catapult 12th Floor Tower Wing Guy s Hospital Great Maze Pond London SE1 9RT +44(0) Catapult is an Innovate UK programme.
HEALTH ECONOMICS AND OUTCOMES RESEARCH SERVICES
HEALTH ECONOMICS AND OUTCOMES RESEARCH SERVICES Health Economics and Outcomes Research cannot operate in a silo. An optimal value proposition requires strong and robust HEOR statements. We develop the
More informationCost Effectiveness, Reimbursement and Medical Devices. Colin Hopley M.Eng MBA MPH
Cost Effectiveness, Reimbursement and Medical Devices Colin Hopley M.Eng MBA MPH Agenda Health Care Environment Policy options - Health Technology Assessment (HTA) - Reimbursement Influence of innovation
More informationEndpoints and quality of life
Endpoints and quality of life PFS, OS, quality of life and medico-economic assessment in oncology Isabelle Durand-Zaleski, Jérôme Garnier, Mira Pavlovic, and participants of roundtable n 3 Pascal Bilbault,
More informationThe fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
More informationCost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.
Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary
More informationCost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness
More informationWhat is costeffectiveness?
...? series Second edition Health economics Supported by sanofi-aventis What is costeffectiveness? Ceri Phillips BSc(Econ) MSc(Econ) PhD Health Economist, Swansea University Cost-effectiveness analysis
More informationRisk-sharing Agreements: Country Experiences and Challenges
Risk-sharing Agreements: Country Experiences and Challenges 101/2014 INSEAD Healthcare Management Initiative www.insead.edu/hmi hmi@insead.edu Written by Ridhima Aggarwal, The Salmon and Rameau Research
More informationPrinciples for application of international reference pricing systems
Principles for application of international reference pricing systems International reference pricing (IRP) is a widely used element of price regulation in the vast majority of EU and EFTA countries. While
More informationAn Introduction to Valuations
An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your
More informationModerator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationApixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/49 This document
More informationChoices in Methods for Economic Evaluation
Choices in Methods for Economic Evaluation A METHODOLOGICAL GUIDE Choices in Methods for Economic Evaluation October 2012 Department of Economics and Public Health Assessment 1 Choices in Methods for Economic
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More information1. Comparative effectiveness of alemtuzumab
Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued
More informationwww.pwc.co.uk/economics Global wage projections to 2030 September 2013
www.pwc.co.uk/economics Global wage projections to 2030 Summary: Wage gap between emerging and advanced economies will shrink significantly by 2030 By 2030, our projections in this report suggest that
More informationCost-Benefit and Cost-Effectiveness Analysis. Kevin Frick, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationGenetic Discoveries and the Role of Health Economics
Genetic Discoveries and the Role of Health Economics Collaboration for Outcome Research and Evaluation (CORE) Faculty of Pharmaceutical Sciences University of British Columbia February 02, 2010 Content
More informationCancer Care Coordinator (CCC) services in colon cancer: economic evaluation using discrete event simulation modelling n
Cancer Care Coordinator (CCC) services in colon cancer: economic evaluation using discrete event simulation modelling n Presenter: Rachel Webber-Foster Co-authors: Lucie Collinson, Giorgi Kvizhinadze,
More informationSummary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
More informationBREVE 6 HEALTH BENEFITS PLANS IN OECD COUNTRIES
BREVE 6 HEALTH BENEFITS PLANS IN OECD COUNTRIES Presentation by Valérie Paris. May 2014 A series on policies and methods based on presentations for experts. Prepared by CRITERIA, a knowledge network on
More informationUNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s)
UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s) Pilot QOF indicator: The percentage of patients 79
More informationLiberating the NHS regulating healthcare providers consultation on proposals
Liberating the NHS regulating healthcare providers consultation on proposals This document is the response from Association of British Healthcare Industries (ABHI) to the consultation above. ABHI has responded
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL
More informationCase study 4 Revlimid and Multiple Myeloma*... Payer approval ...
* Summary Need Revlimid brings benefits to myeloma patients, by slowing disease progressing and lengthening patients lives. Myeloma affects 1.3 in every 10,000 people. In the UK just under 5,000 people
More informationmember of from diagnosis to cure Eucomed Six Key Principles for the Efficient and Sustainable Funding & Reimbursement of Medical Devices
Eucomed Six Key Principles for the Efficient and Sustainable Funding & Reimbursement of Medical Devices Contents Executive Summary 2 Introduction 3 1. Transparency 4 2. Predictability & Consistency 5 3.
More informationNational Centre for Pharmacoeconomics. Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations
National Centre for Pharmacoeconomics Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations Version 1.10 Please Note: This document may be updated periodically, therefore please refer
More informationThe decision making process and the application of value judgments. Francis Ruiz Senior Adviser (Health Economics) NICE International April 2014
The decision making process and the application of value judgments Francis Ruiz Senior Adviser (Health Economics) NICE International April 2014 NICE 2014 Process matters! The ideal situation? Principles
More informationSENSITIVITY ANALYSIS AND INFERENCE. Lecture 12
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationFrench pharmaceutical system Focus on pricing and reimbursement
Couverture French pharmaceutical system Focus on pricing and reimbursement DDGOS date Sophie DELCROIX-LOPES CNAMTS Conflict of interest disclosure 2 The author declares that she has no competing interests.
More informationA competency framework for all prescribers updated draft for consultation
A competency framework for all prescribers updated draft for consultation Consultation closes 15 April 2016 Contents 1 Introduction... 3 2 Uses of the framework... 4 3 Scope of the competency framework...
More informationMost countries will experience an increase in pharmaceutical spending per capita by 2018
6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan
More informationCost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide
More informationMedical Technologies Evaluation Programme Methods guide
Issue date: April 2011 Medical Technologies Evaluation Programme Methods guide National Institute for Health and Clinical Excellence MidCity Place 71 High Holborn London WC1V 6NA www.nice.org.uk National
More informationInternationale Standards des HTA? Jos Kleijnen Kleijnen Systematic Reviews Ltd
Internationale Standards des HTA? Jos Kleijnen Kleijnen Systematic Reviews Ltd Conflicts of Interest A Gutachten was commissioned by VFA we had full editorial freedom Kleijnen Systematic Reviews Ltd has
More informationAn introduction to value-based healthcare in Europe
An article from The Economist Intelligence Unit An introduction to value-based healthcare in Europe European governments, like those in other parts of the world, are feeling the strain on their health
More informationJSA in Germany with BfArM/PEI and G-BA
JSA in Germany with BfArM/PEI and G-BA 16 th DGRA Annual Congress Bonn, 8 May 2014 Thomas Mueller Head of Pharmaceuticals Department Federal Joint Committee (GBA) Seite 3 2014 Thomas Müller AMNOG in brief
More informationEconomic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or
Economic Evaluation of Natalizumab (Tysabri) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated Summary In January 2007 Biogen Idec
More informationA comparative analysis of the role and impact of Health Technology Assessment
FINAL REPORT Prepared For: EFPIA, PhRMA Medicines Australia and EuropaBio A comparative analysis of the role and impact of Health Technology Assessment Prepared By: Tim Wilsdon and Amy Serota 99 Bishopsgate
More informationTherapeutic strategies for the treatment of pain
First EFIC Symposium - Societal Impact of Pain Brussells 4-5 May 2010 Therapeutic strategies for the treatment of pain Paolo D. Siviero Economic Strategy and Pharmaceutical Policy Department Office for
More informationA Health Outcomes Approach to the Pre-Marketing Quantitative Risk-Benefit Modeling of New Pharmaceuticals
A Health Outcomes Approach to the Pre-Marketing Quantitative Risk-Benefit Modeling of New Pharmaceuticals Presentation to Institute of Medicine Forum on Drug Discovery, Development, and Translation: Understanding
More informationexecutive summary Scope Aim and targeted readership
executive summary Scope The development, evaluation and introduction of medical innovations and technologies in general and innovative medical devices in particular are considered an increasingly important
More informationTrastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer Issued: November 2010 guidance.nice.org.uk/ta208 NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationIncorporating Costs into Comparative Effectiveness Research
Research Insights Incorporating Costs into Comparative Effectiveness Research Summary Comparative-effectiveness research attempts to establish the relative health benefits of different drugs, medical devices,
More information2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Rich JD, McKenzie M, Larney S, et al. Methadone
More informationComité Economique des Produits de Santé
Comité Economique des Produits de Santé Summary of the activity report for 1999 CEPS 8 avenue de Ségur 75350 Paris SP 07 Activity Report for 1999 1 In accordance with Article D.162-2-5 of the Social Security
More informationAdalimumab for the treatment of psoriasis
DOI: 10.3310/hta13suppl2/07 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Adalimumab for the treatment of psoriasis D Turner, J Picot,* K Cooper and E Loveman Southampton Health Technology Assessments
More informationData Communications Company (DCC) price control guidance: process and procedures
Guidance document Contact: Tricia Quinn, Senior Economist Publication date: 27 July 2015 Team: Smarter Metering Email: tricia.quinn@ofgem.gov.uk Overview: The Data and Communications Company (DCC) is required
More informationSix Month Pilot Analysis: Improving Rehabilitation for Men with Prostate Cancer in North East London
Six Month Pilot Analysis: Improving Rehabilitation for Men with Prostate Cancer in North East London June 2015 Helen Whitney (Physiotherapist and Prostate Cancer Project Lead) Thufayel Islam (Prostate
More informationOPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS
OPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS April 27 29, 2015 Hyatt Regency Crystal City Arlington, VA, USA 11TH ANNUAL MEETING OF ISMPP 1 ORGANIZED HEALTHCARE
More informationREFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
More informationHow Medical Devices Are Reimbursed in Europe
How Medical Devices Are Reimbursed in Europe Rational decision making in reimbursement decisions to provide optimal care at acceptable cost!? Mattias Kyhlstedt, CEO Synergus AB 1 European Reimbursement:
More informationREPLACED BY "General Methods
Contact: Working Paper Cost Estimation Version 1.0 19/11/2009 Institute for Quality and Efficiency in Health Care (IQWiG) Dillenburger Straße 27 D-51105 Cologne Tel.: +49-221/35685-0 Fax: +49-221/35685-1
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationThe Cell Therapy Catapult
The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing
More informationPolicy proposals to improve access to multiple sclerosis treatments in Europe
Policy proposals to improve access to multiple sclerosis treatments in Europe Key findings and conclusions EMSP Conference Oslo, 17 May 2016 This research builds on a study conducted by CRA in 2014 There
More informationNatalizumab for the treatment of adults with highly active relapsing remitting multiple sclerosis
Natalizumab for the treatment of adults with highly active relapsing remitting multiple sclerosis Premeeting briefing This briefing presents major issues arising from the manufacturer s submission, Evidence
More informationThe NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
More informationRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NHS Evidence has accredited the process used
More informationWhat are the HTA processes in the UK?
What is...? series New title The NHS and HTA Supported by sanofi-aventis What are the HTA processes in the UK? Michael Drummond PhD Professor of Health Economics, Centre for Health Economics, University
More informationHow To Understand The Growth In Private Health Insurance
COMPETITION IN THE AUSTRALIAN PRIVATE HEALTH INSURANCE MARKET Page 1 of 11 1. To what extent has the development of different markets in the various states had an impact on competition? The development
More informationEMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
More informationCommissioning Policy: Defining the boundaries between NHS and Private Healthcare April 2013 Reference : NHSCB/CP/12
Commissioning Policy: Defining the boundaries between NHS and Private Healthcare April 2013 Reference : NHSCB/CP/12 NHS Commissioning Board Commissioning Policy: Defining the Boundaries between NHS and
More informationWhat is health technology assessment?
...? series New title The NHS and HTA Supported by sanofi-aventis What is health technology assessment? Rebecca Taylor MSc Freelance Health Economist Rod Taylor PhD Associate Professor in Health Services
More informationChapter 11 SUPPLEMENTARY FINANCING OPTION (4) VOLUNTARY PRIVATE HEALTH INSURANCE. Voluntary Private Health Insurance as Supplementary Financing
Chapter 11 SUPPLEMENTARY FINANCING OPTION (4) VOLUNTARY PRIVATE HEALTH INSURANCE Voluntary Private Health Insurance as Supplementary Financing 11.1 Voluntary private health insurance includes both employer
More informationREIMBURSEMENT UNRAVELLED: Australia s schizophrenic device coverage system
REIMBURSEMENT UNRAVELLED: Australia s schizophrenic device coverage system Clinica provides you with up to the minute coverage and opinion on company, product, market and regulatory developments as well
More informationValuation of Your Early Drug Candidate. By Linda Pullan, Ph.D. www.sharevault.com. Toll-free USA 800-380-7652 Worldwide 1-408-717-4955
Valuation of Your Early Drug Candidate By Linda Pullan, Ph.D. www.sharevault.com Toll-free USA 800-380-7652 Worldwide 1-408-717-4955 ShareVault is a registered trademark of Pandesa Corporation dba ShareVault
More informationHealth Economics South West Webinar Series 12 October 2015 Rebecca Worboys presenting Nicola Bowtell Facilitating Dominic Gallagher Facilitating
Health Economics South West Webinar Series 12 October 2015 Rebecca Worboys presenting Nicola Bowtell Facilitating Dominic Gallagher Facilitating Rebecca Worboys Health Economist Housekeeping rules Please
More informationTOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS REPORT BY THE DECISION SUPPORT UNIT 2 nd September 2011 Jon Minton, Paul Tappenden, Jonathan Tosh School of Health and Related Research, University
More informationA comparative analysis of the role and impact of Health Technology Assessment: 2013
Prepared For: PhRMA, Suite 300, 950 F Street, NW, Washington, DC 20004 EFPIA, Leopold Plaza Building, Rue du Trône 108, B-1050 Brussels (Belgium) A comparative analysis of the role and impact of Health
More informationThe Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion
November 2013 Edition Vol. 7, Issue 10 The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion By Gordon Gochenauer, Director, Oncology Commercial Strategies,
More informationPOSITION PAPER. Promotion of off-label use of medicines by European healthcare bodies in indications where authorised medicines are available
POSITION PAPER Promotion of off-label use of medicines by European healthcare bodies in indications where authorised medicines are available EFPIA May 2014 EFPIA represents the pharmaceutical industry
More informationHTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More informationATTACHMENT 10 STATEMENT OF REFORM PRIORITIES, CHALLENGER SUBMISSION TO TAX FORUM, OCTOBER 2011
ATTACHMENT 10 STATEMENT OF REFORM PRIORITIES, CHALLENGER SUBMISSION TO TAX FORUM, OCTOBER 2011 Ik A tax plan for our future Stronger. Fairer.Simpler TAX FORD 4-5 October 2011 -qq STATEMENT OF REFORM PRIORITIES
More informationPrivate health insurance: second-best or second-worst solution? Sarah Thomson EHMA VHI MASTERCLASS Milan, 27 June 2013
Private health insurance: second-best or second-worst solution? Sarah Thomson EHMA VHI MASTERCLASS Milan, 27 June 2013 VHI as a policy tool Policy goals Research findings Policy design Regulation Over
More informationClinical trials: The EU perspective. Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission
Clinical trials: The EU perspective Dr Karim Berkouk, Deputy Head of Unit DG for Research and Innovation Health Directorate European Commission Content 1.EU: The global picture 2.EU & Clinial trials: The
More informationRESULTS PRESENTATION. 6 Months ended 30 November 2012 IG NOVEMBER 2012 1
RESULTS PRESENTATION 6 Months ended 30 November 2012 IG NOVEMBER 2012 1 DISCLAIMER IG NOVEMBER 2012 2 OVERVIEW Benefits of IG's scale and market leadership are demonstrated in quieter markets FY13 H1 PERFORMANCE
More informationTeriflunomide for treating relapsing remitting multiple sclerosis
Teriflunomide for treating relapsing remitting multiple Issued: January 2014 last modified: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationDomestic and International Medical Device Reimbursement
Diverse Intelligence Solutions Growth Fuel New Thinking & Innovation Domestic and International Medical Device Reimbursement Deborah Schenberger, Ph.D. OMTEC, 2009 Overview Challenges of reimbursement
More informationFor More Information
CHILDREN AND FAMILIES EDUCATION AND THE ARTS ENERGY AND ENVIRONMENT HEALTH AND HEALTH CARE INFRASTRUCTURE AND TRANSPORTATION The RAND Corporation is a nonprofit institution that helps improve policy and
More informationOrphan drugs: rising to the challenge to ensure a better future for 30 million patients in Europe
www.eurordis.org S T A T E M E N T Orphan drugs: rising to the challenge to ensure a better future for 30 million patients in Europe October 2009 Rare Diseases Europe Summary Nine years after the implementation
More informationHTA and Post-Launch Studies
EXPLORING THE FUTURE OF RE FOR DRUGS IN EUROPE ELEMENTS AFFECTING THE FUTURE OF RE IN EUROPE? Baseline factors Payers continue to face austerity pressures Decision making by Payer / HTA bodies remains
More informationHealth Economics. The Basics. Pat Berrigan Fall 2015
Health Economics The Basics Pat Berrigan Fall 2015 1 Topics 1) What is heath economics and why do we do it; 2) Types of health economic analyses; 3) Cost-effectiveness analysis; 4) The incremental cost-effectiveness
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationAppendix 3 INDIVIDUAL PATIENT DRUG TREATMENT. POLICY AND PROCESS FOR DECISION MAKING September 2007
Appendix 3 INDIVIDUAL PATIENT DRUG TREATMENT POLICY AND PROCESS FOR DECISION MAKING September 2007 Approved by Board: 6 th September 2007 Date Implemented: 1 st October 2007 Review Date: September 2008
More informationPublic / private mix in health care financing
Public / private mix in health care financing Dominique Polton Director of strategy, research and statistics National Health Insurance, France Couverture Public / private mix in health care financing 1.
More informationMy Big Data experience getting my feet wet in the puddle and still treading water 2 years later 28 th June 2013. Rob Walls Healthcare Data Analytics
My Big Data experience getting my feet wet in the puddle and still treading water 2 years later 28 th June 2013 Rob Walls Healthcare Data Analytics Abstract "Big Data" - Electronic Health Records (EHR)
More informationEvidence-based Health Policies for Medical Devices and Diagnostics in Asia. Outline of Presentation
Evidence-based Health Policies for Medical Devices and Diagnostics in Asia Prof Phua Kai Hong Chair, 2007-2008 Asia-Pacific Medical Devices & Diagnostics Council Lee Kuan Yew School of Public Policy The
More informationThe Japan Generic Market Drivers and Obstacles for Change. Matt Heimerdinger Anterio Inc.
The Japan Generic Market Drivers and Obstacles for Change Matt Heimerdinger Anterio Inc. Quick country overview Osaka Tokyo Population: 127,520,000 Life expectancy: Male: 79.9; Female: 86.4 Pharmaceutical
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir
More informationA new value-based approach to the pricing of branded medicines. Submission from the MS Society March 2011
A new value-based approach to the pricing of branded medicines About multiple sclerosis Submission from the MS Society March 2011 Multiple sclerosis (MS) is one of the most common disabling neurological
More informationInsurance and compensation in the event of injury in Phase I clinical trials
Insurance and compensation in the event of injury in Phase I clinical trials Guidance developed by the Association for the British Pharmaceutical Industry, the BioIndustry Association and the Clinical
More informationImproving Quality and Efficiency in Health Care through Comparative Effectiveness Analyses: An International Perspective
Improving Quality and Efficiency in Health Care through Comparative Effectiveness Analyses: An International Perspective by Gerry Fairbrother, Ph.D.; Ellen O Brien, Ph.D.; Rosina Pradhananga, M.P.H.; Kalipso
More information2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
More informationWestern Australian Feed-In Tariff Discussion Paper
Western Australian Feed-In Tariff Discussion Paper OVERVIEW In September 2008, the incoming State Government announced its intention to introduce a feed-in tariff as part of the Liberal Plan for Environmental
More informationRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NICE has accredited the process used by the
More informationStaff Paper 6. Allowed for operating costs. 6.1 Introduction
Staff Paper 6 Allowed for operating costs This staff paper has been produced by our office to assist stakeholders in responding to the Draft Determination. The material reflected in this staff paper has
More information